NASDAQ:CMTA - Clementia Pharmaceuticals Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: N/A
Consensus Price Target: $0.00
Forecasted Upside: -100.00 %
Number of Analysts: 0
Breakdown:
0 Sell Ratings
0 Hold Ratings
0 Buy Ratings
0 Strong Buy Ratings

^$26.35 As of 04/17/2019 01:00 AM ET

+0.30 (1.20%)

Get New Clementia Pharmaceuticals Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CMTA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CMTA

^$0.00

▼ -100.00% Downside Potential

This price target is based on 0 analysts offering 12 month price targets for Clementia Pharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $26.35.

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Clementia Pharmaceuticals. This rating has held steady since March 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
0 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

2/1/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

5/1/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/30/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

10/28/2020

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

1/26/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

4/26/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

6/25/2021

0 strong buy ratings
0 buy ratings
0 hold ratings
0 sell ratings

Ratings as of

7/25/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
3/4/2019	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$27.00	Low
2/26/2019	Bloom Burton	Downgrade	Buy ➝ Hold		Low
2/26/2019	SVB Leerink	Downgrade	Outperform ➝ Market Perform	$26.00	Medium
2/25/2019	Wedbush	Downgrade	Outperform ➝ Neutral		Low
1/18/2019	Robert W. Baird	Initiated Coverage	Outperform ➝ Outperform	$24.00	Medium
12/16/2018	Bloom Burton	Reiterated Rating	Buy		Low
8/15/2018	B. Riley	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $16.00	High
8/13/2018	Morgan Stanley	Lower Price Target	Overweight ➝ Overweight	$27.00 ➝ $26.00	Low
8/10/2018	Wedbush	Reiterated Rating	Outperform	$26.00	Low
3/28/2018	B. Riley	Initiated Coverage	Buy	$25.00	Medium
11/14/2017	Wedbush	Reiterated Rating	Outperform	$26.00	N/A
8/31/2017	BTIG Research	Initiated Coverage	Buy ➝ Buy	$32.00	Low
8/28/2017	SVB Leerink	Initiated Coverage	Outperform ➝ Outperform	$23.00	High
8/28/2017	Wedbush	Initiated Coverage	Outperform ➝ Outperform	$26.00 ➝ $26.00	High
8/28/2017	Morgan Stanley	Initiated Coverage	Overweight ➝ Overweight	$27.00	High

(Data available from 7/25/2016 forward)

Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops treatments for patients suffering from bone disorders and other diseases. Its lead product candidate is palovarotene, an oral small molecule for the treatment of fibrodysplasia ossificans progressive, multiple osteochondromas, dry eye disease, and other diseases is in the Phase 3 MOVE Trial. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.

Today's Range

Now: $26.35

$26.28

$26.69

50 Day Range

MA: $26.35

$26.35

52 Week Range

Now: $26.35

$8.10

$26.73

Volume

716,706 shs

Average Volume

145,059 shs

Market Capitalization

$1.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of Clementia Pharmaceuticals?

The following sell-side analysts have issued stock ratings on Clementia Pharmaceuticals in the last twelve months:
View the latest analyst ratings for CMTA.

What is the current price target for Clementia Pharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Clementia Pharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Clementia Pharmaceuticals in the next year.
View the latest price targets for CMTA.

What is the current consensus analyst rating for Clementia Pharmaceuticals?

Clementia Pharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CMTA.

What other companies compete with Clementia Pharmaceuticals?

Other companies that are similar to Clementia Pharmaceuticals include Arena Pharmaceuticals, Alkermes, Galapagos, Lyell Immunopharma, Karuna Therapeutics, Emergent BioSolutions, ACADIA Pharmaceuticals, Turning Point Therapeutics, Cerevel Therapeutics, Agios Pharmaceuticals, Nektar Therapeutics, Intra-Cellular Therapies, Rocket Pharmaceuticals, PTC Therapeutics and Dicerna Pharmaceuticals.

How do I contact Clementia Pharmaceuticals' investor relations team?

Clementia Pharmaceuticals' physical mailing address is 4150 ST CATHERINE STREET WEST SUITE 550, MONTREAL A8, H3Z 2Y5. The company's listed phone number is 514-940-3600 and its investor relations email address is [email protected] The official website for Clementia Pharmaceuticals is www.clementiapharma.com.